Cargando…
Rivastigmine for the treatment of dementia associated with Parkinson’s disease
Parkinson’s disease (PD) afflicts millions of people worldwide and leads to cognitive impairment or dementia in the majority of patients over time. Parkinson’s disease dementia (PDD) is characterized by deficits in attention, executive and visuospatial function, and memory. The clinical diagnostic c...
Autores principales: | Reingold, Jennifer L, Morgan, John C, Sethi, Kapil D |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2656320/ https://www.ncbi.nlm.nih.gov/pubmed/19300613 |
Ejemplares similares
-
Rivastigmine in the treatment of patients with Alzheimer’s disease
por: Müller, Thomas
Publicado: (2007) -
Rasagiline in treatment of Parkinson’s disease
por: Nayak, Lakshmi, et al.
Publicado: (2008) -
Update on ropinirole in the treatment of Parkinson’s disease
por: Shill, Holly A, et al.
Publicado: (2009) -
Update on the use of pramipexole in the treatment of Parkinson’s disease
por: Constantinescu, Radu
Publicado: (2008) -
Once-daily pramipexole for the treatment of early and advanced idiopathic Parkinson’s disease: implications for patients
por: Antonini, Angelo, et al.
Publicado: (2011)